Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Cerenome

14/08/2026 21:46

Plus Therapeutics Inc CNSY.OQ reported a quarterly adjusted loss of $1.31​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 50 cents.  The mean expectation of four analysts for the quarter was for a loss of 91 cents per share. Wall Street expected results to range from -100 cents to -79 cents per share.
Revenue fell 70.4% to $411.00 thousand from a year ago; analysts expected $1.11 million. 
Plus Therapeutics Inc's reported EPS for the quarter was a loss of $1.31​.
The company reported a quarterly loss of $9.01 million.
Plus Therapeutics Inc shares had fallen by 15.3% this quarter and lost 71.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Plus Therapeutics Inc is $37.50, about 90.1% above its last closing price of $3.70
This summary was machine generated from LSEG data August 14 at 08:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.91
-1.31
Missed
Mar. 31 2026 
-0.88
-1.05
Missed
Dec. 31 2025 
-0.81
-1.04
Missed
Sep. 30 2025 
-0.50
-1.00
Missed